Richard Pulik sold $9.1M of ROIV
CFO at Roivant Sciences Ltd.. 406,731 shares at an average of $22.43, traded Dec 23, 2025, filed Dec 29, 2025.
Score components
- +22RoleCFO
- +25Trade size$9.1M at market
- +20Share of holdings soldSold 63% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-046787, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2025 | MOption exercise Common Shares | +260,000 | $3.85 | $1.0M | 646,144 | Dec 29, 2025 |
| Dec 23, 2025 | SOpen-market sale Common Shares | -260,000 | $22.45 | $5.8M | 386,144 | Dec 29, 2025 |
| Dec 23, 2025 | SOpen-market sale Common Shares | -146,731 | $22.39 | $3.3M | 239,413 | Dec 29, 2025 |
| Dec 23, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -260,000 | $0.00 | $0 | 740,000 | Dec 29, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 45Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $29M 1,330,868 shares | -7% | |
| 55Moderate | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $6.2M 275,000 shares | -15% | |
| 40Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $620k 26,831 shares | -0% | |
| 55Moderate | Roivant Sciences Ltd. | Daniel Allen Gold director | $39M 1,694,614 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.